{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:02:52Z","timestamp":1788984172205,"version":"build-2803163510"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T00:00:00Z","timestamp":1516665600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008725","name":"Agencia Nacional de Investigaci\u00f3n e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["FMV_1_2011_1_7181"],"award-info":[{"award-number":["FMV_1_2011_1_7181"]}],"id":[{"id":"10.13039\/100008725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00007","type":"journal-article","created":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T04:17:27Z","timestamp":1516681047000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Salmonella Immunotherapy Improves the Outcome of CHOP Chemotherapy in Non-Hodgkin Lymphoma-Bearing Mice"],"prefix":"10.3389","volume":"9","author":[{"given":"Thais","family":"Bascuas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Grille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Chabalgoity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,1,23]]},"reference":[{"key":"B1","article-title":"Non-Hodgkin\u2019s lymphomas","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Version 4","author":"Zelenetz","year":"2014"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1586\/era.09.86","article-title":"Emerging therapies for B-cell non-Hodgkin lymphoma","volume":"9","author":"Briones","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1177\/1535370213498985","article-title":"Non-Hodgkin\u2019s B-cell lymphoma: advances in molecular strategies targeting drug resistance","volume":"238","author":"Maxwell","year":"2013","journal-title":"Exp Biol Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2015.11.001","article-title":"Targeting B-cell non Hodgkin lymphoma: new and old tricks","volume":"42","author":"Solimando","year":"2016","journal-title":"Leuk Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1586\/14760584.1.4.495","article-title":"Live bacteria as the basis for immunotherapies against cancer","volume":"1","author":"Chabalgoity","year":"2002","journal-title":"Expert Rev Vaccines"},{"key":"B6","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S1470-2045(03)01194-X","article-title":"Bacteria as tumour-targeting vectors","volume":"4","author":"Pawelek","year":"2003","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/8451728","article-title":"Bacteria in cancer therapy: renaissance of an old concept","volume":"2016","author":"Felgner","year":"2016","journal-title":"Int J Microbiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2174\/156652310790945566","article-title":"Salmonella as live trojan horse for vaccine development and cancer gene therapy","volume":"10","author":"Moreno","year":"2010","journal-title":"Curr Gene Ther"},{"key":"B9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.18388\/abp.2013_1984","article-title":"Salmonella and cancer: from pathogens to therapeutics","volume":"60","author":"Chorobik","year":"2013","journal-title":"Acta Biochim Pol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s13139-016-0415-z","article-title":"Salmonella-mediated cancer therapy: roles and potential","volume":"51","author":"Nguyen","year":"2017","journal-title":"Nucl Med Mol Imaging"},{"key":"B11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/jgm","article-title":"Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma","volume":"9","author":"Agorio","year":"2007","journal-title":"J Gene Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00109-010-0636-z","article-title":"Salmonella-allies in the fight against cancer","volume":"88","author":"Leschner","year":"2010","journal-title":"J Mol Med"},{"key":"B13","first-page":"4537","article-title":"Tumor-targeted Salmonella as a novel anticancer vector","volume":"57","author":"Pawelek","year":"1997","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1158\/0008-5472.CAN-04-3002","article-title":"Cancer immunotherapy based on killing of Salmonella-infected tumor cells","volume":"10","author":"Avogadri","year":"2005","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.20452\/pamw.1117","article-title":"Therapeutic vaccines based on genetically modified Salmonella: a novel strategy in cancer immunotherapy","volume":"121","author":"Chorobik","year":"2011","journal-title":"Pol Arch Med Wewn"},{"key":"B16","doi-asserted-by":"publisher","first-page":"14546","DOI":"10.3390\/ijms150814546","article-title":"Salmonella as an innovative therapeutic antitumor agent","volume":"15","author":"Chang","year":"2014","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.4161\/hv.24917","article-title":"Potential therapeutic anti-tumor effect of a Salmonella-based vaccine","volume":"9","author":"Chang","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4068\/cmj.2016.52.3.173","article-title":"Targeted cancer therapy using engineered Salmonella typhimurium","volume":"52","author":"Zheng","year":"2016","journal-title":"Chonnam Med J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S0264-410X(00)00197-3","article-title":"Salmonella typhimurium as a basis for a live oral Echinococcus granulosus vaccine","volume":"19","author":"Chabalgoity","year":"2000","journal-title":"Vaccine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.neuroscience.2005.02.031","article-title":"Mucosal vaccination delays or prevents prion infection via an oral route","volume":"133","author":"Go\u00f1i","year":"2005","journal-title":"Neuroscience"},{"key":"B21","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.neuroscience.2008.02.051","article-title":"High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice","volume":"153","author":"Go\u00f1i","year":"2008","journal-title":"Neuroscience"},{"key":"B22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/vim.2011.0031","article-title":"Immunogenicity of a bovine herpes virus I peptide expressed in tandem copies in attenuated Salmonella","volume":"25","author":"Gnazzo","year":"2012","journal-title":"Viral Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1371\/journal.pntd.0000125","article-title":"An oral recombinant vaccine in dogs against Echinococcus granulosus, the causative agent of human hydatid disease: a pilot study","volume":"2","author":"Petavy","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.leukres.2012.10.003","article-title":"A therapeutic vaccine using Salmonella-modified tumor cells combined with interleukin-2 induces enhanced antitumor immunity in B-cell lymphoma","volume":"37","author":"Grille","year":"2013","journal-title":"Leuk Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/imm.12320","article-title":"Salmonella enterica serovar typhimurium immunotherapy for B-cell lymphoma induces broad antitumor immunity with therapeutic effect","volume":"143","author":"Grille","year":"2014","journal-title":"Immunology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1186\/s12885-015-1618-x","article-title":"Neoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated Salmonella eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice","volume":"15","author":"Kramer","year":"2015","journal-title":"BMC Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.imbio.2015.12.010","article-title":"Lymphoma immunotherapy: current status","volume":"6","author":"Zappasodi","year":"2015","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"key":"B29","first-page":"46","article-title":"Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes","volume":"4","author":"Baio","year":"2014","journal-title":"Am J Blood Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/477526a","article-title":"Translational research: 4 ways to fix the clinical trial","volume":"477","author":"Ledford","year":"2011","journal-title":"Nature"},{"key":"B31","first-page":"1172","article-title":"Antitumor vaccination: where we stand","volume":"85","author":"Bocchia","year":"2000","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12967-016-1073-8","article-title":"A novel non-Hodgkin lymphoma murine model closer to the standard clinical scenario","volume":"14","author":"Bascuas","year":"2016","journal-title":"J Transl Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00262-009-0768-6","article-title":"A B-cell lymphoma vaccine using a depot formulation of interleukin-2 induces potent antitumor immunity despite increased numbers of intratumoral regulatory T cells","volume":"59","author":"Grille","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1056\/NEJM199211053271903","article-title":"Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin\u2019s lymphoma","volume":"327","author":"Gordon","year":"1992","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2^(-\u0394\u0394CT) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"B36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/9780470942390.mo110217.Health","article-title":"Health evaluation of experimental laboratory mice","volume":"2","author":"Burkholder","year":"2012","journal-title":"Curr Protoc Mouse Biol"},{"key":"B37","first-page":"319","article-title":"Body condition scoring: a rapid and accurate method for assessing health status in mice","volume":"49","author":"Ullman-Culler\u00e9","year":"1999","journal-title":"Lab Anim Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nmeth.1455","article-title":"Coding of facial expressions of pain in the laboratory mouse","volume":"7","author":"Langford","year":"2010","journal-title":"Nat Methods"},{"key":"B39","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/ijc.22688","article-title":"Tumor-targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model","volume":"121","author":"Jia","year":"2007","journal-title":"Int J Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ymthe.2005.01.008","article-title":"Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy","volume":"11","author":"Lee","year":"2005","journal-title":"Mol Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nature18930","article-title":"Synchronized cycles of bacterial lysis for in vivo delivery","volume":"536","author":"Din","year":"2016","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: a systematic review","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"651","DOI":"10.7150\/ijbs.7.651","article-title":"Dual roles of immune cells and their factors in cancer development and progression","volume":"7","author":"Zamarron","year":"2011","journal-title":"Int J Biol Sci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pharmthera.2016.09.011","article-title":"Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment","volume":"168","author":"Atretkhany","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.vaccine.2013.01.006","article-title":"Intratumoral injection of attenuated Salmonella vaccine can induce tumor microenvironmental shift from immune suppressive to immunogenic","volume":"31","author":"Hong","year":"2013","journal-title":"Vaccine"},{"key":"B46","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00280-016-3152-1","article-title":"The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy","volume":"78","author":"Ahlmann","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2249.2012.04657.x","article-title":"Suppression, subversion and escape: the role of regulatory T cells in cancer progression","volume":"171","author":"Oleinika","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/CJI.0b013e3182886d95","article-title":"Therapeutic effects of Salmonella typhi in a mouse model of T-cell lymphoma","volume":"36","author":"Vendrell","year":"2013","journal-title":"J Immunother"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1084\/jem.168.6.2251","article-title":"Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1\u03b2","volume":"168","author":"Sherry","year":"1988","journal-title":"J Exp Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0065-230X(10)06003-3","article-title":"CXC chemokines in cancer angiogenesis and metastases","volume":"106","author":"Keeley","year":"2010","journal-title":"Adv Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/82","article-title":"Role of chemokines in the biology of natural killer cells","volume":"341","author":"Maghazachi","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ni.3518","article-title":"Targeting natural killer cells in cancer immunotherapy","volume":"17","author":"Guillerey","year":"2016","journal-title":"Nat Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.blre.2016.08.007","article-title":"Natural killer cells in malignant hematology: a primer for the non-immunologist","volume":"31","author":"Kannan","year":"2017","journal-title":"Blood Rev"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/5230219","article-title":"Immune cells in cancer therapy and drug delivery","author":"Eyileten","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/8941260","article-title":"Effector, memory, and dysfunctional CD8+ T cell fates in the antitumor immune response","author":"Reiser","year":"2016","journal-title":"J Immunol Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/onc.2015.139","article-title":"CXCL12\/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks","volume":"35","author":"Guo","year":"2016","journal-title":"Oncogene"},{"key":"B58","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.apsb.2015.07.005","article-title":"Cancer metastases: challenges and opportunities","volume":"5","author":"Guan","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"B59","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.canlet.2015.10.009","article-title":"Immunotherapy and tumor microenvironment","volume":"370","author":"Tang","year":"2016","journal-title":"Cancer Lett"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","article-title":"Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment","volume":"69","author":"Harlin","year":"2009","journal-title":"Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ajpath.2011.03.007","article-title":"Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling","volume":"179","author":"Coppola","year":"2011","journal-title":"Am J Pathol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/srep00765","article-title":"12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?","volume":"2","author":"Messina","year":"2012","journal-title":"Sci Rep"},{"key":"B63","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.imlet.2016.05.018","article-title":"Chemokine genetic polymorphism in human health and disease","volume":"176","author":"Qidwai","year":"2016","journal-title":"Immunol Lett"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e29899","DOI":"10.4161\/mco.29899","article-title":"Role of macrophage inflammatory protein (MIP)-1alpha\/CCL3 in leukemogenesis","volume":"1","author":"Baba","year":"2014","journal-title":"Mol Cell Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10456-014-9454-1","article-title":"CXCL1 promotes arteriogenesis through enhanced monocyte recruitment into the peri-collateral space","volume":"18","author":"Vries","year":"2015","journal-title":"Angiogenesis"},{"key":"B66","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cytogfr.2011.09.002","article-title":"The expression and role of CXC chemokines in colorectal cancer","volume":"22","author":"Verbeke","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"key":"B67","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.bbcan.2014.01.004","article-title":"Tumor-induced perturbations of cytokines and immune cell networks","volume":"1845","author":"Burkholder","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B68","doi-asserted-by":"publisher","first-page":"137R","DOI":"10.1093\/glycob\/cwl025","article-title":"Galectin-1: a small protein with major functions","volume":"16","author":"Camby","year":"2006","journal-title":"Glycobiology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/ijms17091566","article-title":"The role of galectin-1 in cancer progression, and synthetic multivalent systems for the study of galectin-1","volume":"17","author":"Cousin","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B70","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/glycob\/cwu048","article-title":"Galectin-1 and -9 in angiogenesis: a sweet couple","volume":"24","author":"Lthijssen","year":"2014","journal-title":"Glycobiology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ctrv.2013.07.007","article-title":"Unraveling galectin-1 as a novel therapeutic target for cancer","volume":"40","author":"Astorgues-Xerri","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"B72","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbcan.2015.03.003","article-title":"Galectin expression in cancer diagnosis and prognosis: a systematic review","volume":"1855","author":"Thijssen","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"B73","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/MOH.0b013e328362370f","article-title":"Galectins in hematological malignancies","volume":"20","author":"Giordano","year":"2013","journal-title":"Curr Opin Hematol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2217\/fon.15.57","article-title":"A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin\u2019s lymphomas","volume":"11","author":"Feugier","year":"2015","journal-title":"Future Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/701704","article-title":"Murine models of B-cell lymphomas: promising tools for designing cancer therapies","author":"Donnou","year":"2012","journal-title":"Adv Hematol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1080\/10428190500221454x","article-title":"The natural history of a novel, systemic, disseminated model of syngeneic mouse B-cell lymphoma","volume":"46","author":"Passineau","year":"2005","journal-title":"Leuk Lymphoma"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00007\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T23:40:20Z","timestamp":1751240420000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00007\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,23]]},"references-count":76,"alternative-id":["10.3389\/fimmu.2018.00007"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00007","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,23]]},"article-number":"7"}}